DOCSLIB.ORG

Targeting Glutamine Metabolism Rescues Mice from Late-Stage Cerebral Malaria

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Targeting Glutamine Metabolism Rescues Mice from Late-Stage Cerebral Malaria Targeting glutamine metabolism rescues mice from late-stage cerebral malaria Emile B. Gordona,1,2, Geoffrey T. Harta,1, Tuan M. Trana,1,3, Michael Waisberga,4, Munir Akkayaa, Ann S. Kima, Sara E. Hamiltonb, Mirna Penaa, Takele Yazewa, Chen-Feng Qia, Chen-Fang Leec,d, Ying-Chun Loc, Louis H. Millere,5, Jonathan D. Powellc,5, and Susan K. Piercea,5 aLaboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852; bDepartment of Laboratory Medicine and Pathology, Center for Immunology, University of Minnesota Medical School, Minneapolis, MN 55454; cSidney Kimmel Comprehensive Cancer Research Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287; dChang-Gung Transplantation Institute, Department of Liver and Transplantation Surgery, Chang-Gung Memorial Hospital, Taoyuan 333, Taiwan; and eLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852 Contributed by Louis H. Miller, August 26, 2015 (sent for review June 19, 2015; reviewed by James R. Mitchell) + The most deadly complication of Plasmodium falciparum infection intravasculature leukocytes, including CD8 T cells, sequestered in the + + is cerebral malaria (CM) with a case fatality rate of 15–25% in brain vessels (13, 14). In ECM monocytes and both CD4 and CD8 T African children despite effective antimalarial chemotherapy. cells have been shown to accumulate in the brain by both flow There are no adjunctive treatments for CM, so there is an urgent cytometry and by intravital imaging (15). Current evidence indicates + need to identify new targets for therapy. Here we show that the that CD8 T cells are the major mediators of death in ECM (16) and + glutamine analog 6-diazo-5-oxo-L-norleucine (DON) rescues mice that antigen-specific CD8 T cells engage parasite antigens cross-pre- from CM when administered late in the infection a time at which sented on MHC class I molecules on brain endothelium, resulting in mice already are suffering blood–brain barrier dysfunction, brain endothelial cell dysfunction by a perforin-dependent mechanism (17). swelling, and hemorrhaging accompanied by accumulation of par- A critical role for metabolic reprogramming in regulating immune + asite-specific CD8 effector T cells and infected red blood cells in responses is becoming increasingly appreciated. Upon activation, T cells the brain. Remarkably, within hours of DON treatment mice showed undergo metabolic reprogramming to meet the increased energetic and blood–brain barrier integrity, reduced brain swelling, decreased biosynthetic demands of growth and effector T-cell functions (18–20). function of activated effector CD8+ T cells in the brain, and levels Reprogramming involves a shift to aerobic glycolysis and increased of brain metabolites that resembled those in uninfected mice. glutaminolysis. Activated T cells import large quantities of Gln and These results suggest DON as a strong candidate for an effective increase their expression of glutaminase (21–23). Because the pathology adjunctive therapy for CM in African children. leading to death in CM is believed to be in part immune mediated, we hypothesized that blocking T-cell metabolism might effectively mitigate + cerebral malaria | adjunctive therapy | CD8 T cells | glutamine the pathology leading to death in HCM. To this end, in the present metabolism | DON Significance MICROBIOLOGY he World Health Organization estimates that there are nearly T200 million clinical cases of Plasmodium falciparum malaria Cerebral malaria (CM) is a deadly complication of Plasmodium annually (1). For most individuals living in endemic areas, malaria falciparum infection in African children despite effective anti- is uncomplicated and resolves with time. However, in about 1% of malarial treatment. Once signs of neurologic disease have cases, almost exclusively among young children, malaria becomes commenced, there is no adjunctive treatment for CM, and severe and life threatening, resulting in 525,000 deaths each year overall mortality remains high. Thus, a treatment that arrests in Africa alone. One of the most deadly complications of P. fal- disease and promotes healing in the late stages is urgently ciparum infection in humans is cerebral malaria (HCM) charac- needed. Here we report, in an animal model of CM, that the terized by the onset of severe neurological signs such as altered glutamine analog 6-diazo-5-oxo-L-norleucine (DON) is an ef- consciousness, seizures, and coma (2). Autopsy and MRI analyses fective therapy even when treatment is initiated after infected of brains of children with HCM indicate sequestration of infected animals show neurological signs of disease. Within hours of – red blood cells (iRBCs), microhemorrhaging, breakdown of the DON treatment blood brain barrier integrity was restored, and blood–brain barrier (BBB) (3), and a fatal increase in intracranial brain swelling was reduced. These results suggest DON as a pressure resulting from edema (4, 5). At present, despite effective strong candidate for an effective adjunctive therapy for CM in antimalarial drug treatment, mortality for children presenting with African children. HCM remains high, at 15–25%. HCM takes a second toll on Author contributions: E.B.G., G.T.H., T.M.T., M.W., L.H.M., J.D.P., and S.K.P. designed re- African children, leaving survivors at risk for debilitating neuro- search; E.B.G., G.T.H., T.M.T., M.W., M.A., A.S.K., S.E.H., M.P., T.Y., C.-F.Q., C.-F.L., and Y.-C.L. logical defects (6). Thus, there is an urgent need for the devel- performed research; E.B.G., G.T.H., T.M.T., M.W., M.A., A.S.K., C.-F.Q., C.-F.L., Y.-C.L., and J.D.P. opment of effective adjunctive therapies that can be used in analyzed data; and E.B.G., G.T.H., T.M.T., L.H.M., J.D.P., and S.K.P. wrote the paper. conjunction with antimalarials to treat children with HCM. Reviewers included: J.R.M., Harvard School of Public Health. Experimental cerebral malaria (ECM) in mice is a widely used The authors declare no conflict of interest. model of HCM and provides a valuable tool for elucidating the 1E.B.G., G.T.H., and T.M.T. contributed equally to this work. mechanisms involved in CM pathogenesis and identifying cellular 2Present address: Perelman School of Medicine, University of Pennsylvania, Philadelphia, and molecular targets for adjunctive therapy (7). In ECM, 6–7dafter PA 19104. infection with Plasmodium berghei ANKA (PbA), mice of susceptible 3Present address: Division of Infectious Diseases, Indiana University School of Medicine, strains, such as C57BL/6, develop ataxia, paralysis, seizures, and coma Indianapolis, IN 46202. and ultimately die (8). ECM displays key features of HCM, including 4Present address: Department of Pathology, University of Virginia School of Medicine, BBB breakdown, focal hemorrhaging, and brain swelling (9–11). Charlottesville, VA 22903. ’ ECM s pathology also requires sequestration of iRBCs in the brain 5To whom correspondence may be addressed. Email: [email protected], Jpowell@jhmi. vasculature (12), a hallmark of HCM (3). Histological analysis of the edu, or [email protected]. brains of children who died of HCM showed leukocytes, primarily This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. monocytes with phagocytized hemozoin and platelets but also 1073/pnas.1516544112/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1516544112 PNAS | October 20, 2015 | vol. 112 | no. 42 | 13075–13080 Downloaded by guest on October 1, 2021 A C signs) to 10 (moribund) using previously described criteria (25). 15 No Rx Nearly all the untreated mice that were infected with PbA developed 100 No Rx DON Rx d5a DON Rx d5a neurological signs by day 5p p.i. that in most cases were severe 10 DON Rx d5p DON Rx d5p DON Rx d6a > DON Rx d6a (clinical score 6) by day 6a p.i. (Fig. 1B). Treatment with DON 50 5 beginning on day 5a p.i. prevented the development of neurological % Survival % symptoms in all PbA-infected mice (Fig. 1B). Treatment of mice with % Parasitemia 0 0 456789 DON beginning on day 5p p.i., a point at which most mice had 0510 Day p.i. Day/Time p.i. clinical scores of 2, not only prevented the worsening of clinical signs B D but promoted the rapid resolution of symptoms (Fig. 1B). Re- 10 4 No Rx n.s. markably, treatment of mice on day 6a p.i., when many mice already DON Rx d5a F.C. 3 DON Rx d5p had developed clinical scores of 5, blocked the progression of the 5 DON Rx d6a 2 disease and rapidly resolved the symptoms in half of the mice (Fig. A 18s 1B). Thus, DON was able to arrest disease and promote healing even (d5p to d6a) to (d5p Pb 1 Clinical Score Clinical when the mice already were displaying signs of neurologic damage. 0 0 5678910 PbA infected: + + A scatter plot showing the clinical scores of individual mice on the DON Rx day p.i.: - d5p Day/Time p.i. RNA day p.i.: d6a d6a day of treatment and the resulting outcome of treatment is given in Fig. S2. For mice treated with DON on d5p p.i., the clinical scores on Fig. 1. DON treatment reduced the mortality associated with ECM. C57BL/6 the day of DON treatment (which ranged from 0 to 6) did not dis- mice were infected with PbA on day 0 and were injected i.p. with saline tinguish the mice that survived from those that died, even though the = (NoRx) (n 49) or with DON (1.3 mg/kg) beginning on day 5 p.i. at 7:00 AM average clinical score was significantly higher for mice that died (DON Rx d5a) (n = 28), on day 5 p.i.
Load more

Recommended publications
  • 35 Disorders of Purine and Pyrimidine Metabolism
    35 Disorders of Purine and Pyrimidine Metabolism Georges van den Berghe, M.- Françoise Vincent, Sandrine Marie 35.1 Inborn Errors of Purine Metabolism – 435 35.1.1 Phosphoribosyl Pyrophosphate Synthetase Superactivity – 435 35.1.2 Adenylosuccinase Deficiency – 436 35.1.3 AICA-Ribosiduria – 437 35.1.4 Muscle AMP Deaminase Deficiency – 437 35.1.5 Adenosine Deaminase Deficiency – 438 35.1.6 Adenosine Deaminase Superactivity – 439 35.1.7 Purine Nucleoside Phosphorylase Deficiency – 440 35.1.8 Xanthine Oxidase Deficiency – 440 35.1.9 Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency – 441 35.1.10 Adenine Phosphoribosyltransferase Deficiency – 442 35.1.11 Deoxyguanosine Kinase Deficiency – 442 35.2 Inborn Errors of Pyrimidine Metabolism – 445 35.2.1 UMP Synthase Deficiency (Hereditary Orotic Aciduria) – 445 35.2.2 Dihydropyrimidine Dehydrogenase Deficiency – 445 35.2.3 Dihydropyrimidinase Deficiency – 446 35.2.4 Ureidopropionase Deficiency – 446 35.2.5 Pyrimidine 5’-Nucleotidase Deficiency – 446 35.2.6 Cytosolic 5’-Nucleotidase Superactivity – 447 35.2.7 Thymidine Phosphorylase Deficiency – 447 35.2.8 Thymidine Kinase Deficiency – 447 References – 447 434 Chapter 35 · Disorders of Purine and Pyrimidine Metabolism Purine Metabolism Purine nucleotides are essential cellular constituents 4 The catabolic pathway starts from GMP, IMP and which intervene in energy transfer, metabolic regula- AMP, and produces uric acid, a poorly soluble tion, and synthesis of DNA and RNA. Purine metabo- compound, which tends to crystallize once its lism can be divided into three pathways: plasma concentration surpasses 6.5–7 mg/dl (0.38– 4 The biosynthetic pathway, often termed de novo, 0.47 mmol/l). starts with the formation of phosphoribosyl pyro- 4 The salvage pathway utilizes the purine bases, gua- phosphate (PRPP) and leads to the synthesis of nine, hypoxanthine and adenine, which are pro- inosine monophosphate (IMP).
    [Show full text]
  • The Biochemistry of Gout: a USMLE Step 1 Study Aid
    The Biochemistry of Gout: A USMLE Step 1 Study Aid BMS 6204 May 26, 2005 Compiled by: Todd Kerensky Elizabeth Ballard Brendan Prendergast Eric Ritchie 1 Introduction Gout is a systemic disease caused by excess uric acid as the result of deficient purine metabolism. Clinically, gout is marked by peripheral arthritis and painful inflammation in joints resulting from deposition of uric acid in joint synovia as monosodium urate crystals. Although gout is the most common crystal-induced arthritis, a condition known as pseudogout can commonly be mistaken for gout in the clinic. Pseudogout results from deposition of calcium pyrophosphatase (CPP) crystals in synovial spaces, but causes nearly identical clinical presentation. Clinical findings Crystal-induced arthritis such as gout and pseudogout differ from other types of arthritis in their clinical presentations. The primary feature differentiating gout from other types of arthritis is the spontaneity and abruptness of onset of inflammation. Additionally, the inflammation from gout and pseudogout are commonly found in a single joint. Gout and pseudogout typically present with Podagra, a painful inflammation of the metatarsal- phalangeal joint of the great toe. However, gout can also present with spontaneous edema and painful inflammation of any other joint, but most commonly the ankle, wrist, or knee. As an exception, a spontaneous painful inflammation in the glenohumeral joint is usually the result of pseudogout. It is important to recognize the clinical differences between gout, pseudogout and other types of arthritis because the treatments differ markedly (Kaplan 2005). Pathophysiology and Treatment of Gout Although gout affects peripheral joints in clinical presentation, it is important to recognize that it is a systemic disorder caused by either overproduction or underexcretion of uric acid.
    [Show full text]
  • The Link Between Purine Metabolism and Production of Antibiotics in Streptomyces
    antibiotics Review The Link between Purine Metabolism and Production of Antibiotics in Streptomyces Smitha Sivapragasam and Anne Grove * Department of Biological Sciences, Louisiana State University, Baton Rouge, LA 70803, USA; [email protected] * Correspondence: [email protected] Received: 10 May 2019; Accepted: 3 June 2019; Published: 6 June 2019 Abstract: Stress and starvation causes bacterial cells to activate the stringent response. This results in down-regulation of energy-requiring processes related to growth, as well as an upregulation of genes associated with survival and stress responses. Guanosine tetra- and pentaphosphates (collectively referred to as (p)ppGpp) are critical for this process. In Gram-positive bacteria, a main function of (p)ppGpp is to limit cellular levels of GTP, one consequence of which is reduced transcription of genes that require GTP as the initiating nucleotide, such as rRNA genes. In Streptomycetes, the stringent response is also linked to complex morphological differentiation and to production of secondary metabolites, including antibiotics. These processes are also influenced by the second messenger c-di-GMP. Since GTP is a substrate for both (p)ppGpp and c-di-GMP, a finely tuned regulation of cellular GTP levels is required to ensure adequate synthesis of these guanosine derivatives. Here, we discuss mechanisms that operate to control guanosine metabolism and how they impinge on the production of antibiotics in Streptomyces species. Keywords: c-di-GMP; guanosine and (p)ppGpp; purine salvage; secondary metabolism; Streptomycetes; stringent response 1. Introduction Bacteria experience constant challenges, either in the environment or when infecting a host. They utilize various mechanisms to survive such stresses, which may include changes in temperature, pH, or oxygen content as well as limited access to carbon or nitrogen sources.
    [Show full text]
  • Effects of Allopurinol and Oxipurinol on Purine Synthesis in Cultured Human Cells
    Effects of allopurinol and oxipurinol on purine synthesis in cultured human cells William N. Kelley, James B. Wyngaarden J Clin Invest. 1970;49(3):602-609. https://doi.org/10.1172/JCI106271. Research Article In the present study we have examined the effects of allopurinol and oxipurinol on thed e novo synthesis of purines in cultured human fibroblasts. Allopurinol inhibits de novo purine synthesis in the absence of xanthine oxidase. Inhibition at lower concentrations of the drug requires the presence of hypoxanthine-guanine phosphoribosyltransferase as it does in vivo. Although this suggests that the inhibitory effect of allopurinol at least at the lower concentrations tested is a consequence of its conversion to the ribonucleotide form in human cells, the nucleotide derivative could not be demonstrated. Several possible indirect consequences of such a conversion were also sought. There was no evidence that allopurinol was further utilized in the synthesis of nucleic acids in these cultured human cells and no effect of either allopurinol or oxipurinol on the long-term survival of human cells in vitro could be demonstrated. At higher concentrations, both allopurinol and oxipurinol inhibit the early steps ofd e novo purine synthesis in the absence of either xanthine oxidase or hypoxanthine-guanine phosphoribosyltransferase. This indicates that at higher drug concentrations, inhibition is occurring by some mechanism other than those previously postulated. Find the latest version: https://jci.me/106271/pdf Effects of Allopurinol and Oxipurinol on Purine Synthesis in Cultured Human Cells WILLIAM N. KELLEY and JAMES B. WYNGAARDEN From the Division of Metabolic and Genetic Diseases, Departments of Medicine and Biochemistry, Duke University Medical Center, Durham, North Carolina 27706 A B S TR A C T In the present study we have examined the de novo synthesis of purines in many patients.
    [Show full text]
  • Study of Purine Metabolism in a Xanthinuric Female
    Study of Purine Metabolism in a Xanthinuric Female MICHAEL J. BRADFORD, IRWIN H. KRAKOFF, ROBERT LEEPER, and M. EARL BALis From the Sloan-Kettering Institute, Sloan-Kettering Division of Cornell University Graduate School of Medical Sciences, and the Department of Medicine of Memorial and James Ewing Hospitals, New York 10021 A B S TR A C T A case of xanthinuria is briefly de- Case report in brief. The patient is a 62 yr old scribed, and the results of in vivo studies with Puerto Rican grandmother, whose illness is de- 4C-labeled oxypurines are discussed. The data scribed in detail elsewhere.' Except for mild pso- demonstrate that the rate of the turnover of uric riasis present for 30 yr, she has been in good acid is normal, despite an extremely small uric health. On 26 June 1966, the patient was admitted acid pool. Xanthine and hypoxanthine pools were to the Second (Cornell) Medical Service, Bellevue measured and their metabolism evaluated. The Hospital, with a 3 day history of pain in the right bulk of the daily pool of 276 mg of xanthine, but foot and fever. The admission physical examina- only 6% of the 960 mg of hypoxanthine, is ex- tion confirmed the presence of monoarticular ar- creted. Thus, xanthine appears to be a metabolic thritis and mild psoriasis. The patient's course in end product, whereas hypoxanthine is an active the hospital was characterized by recurrent fevers intermediate. Biochemical implications of this find- to 104°F and migratory polyarthritis, affecting ing are discussed. both ankles, knees, elbows, wrists, and hands over a 6 wk period.
    [Show full text]
  • Implications of Oxidative Stress in Glioblastoma Multiforme Following Treatment with Purine Derivatives
    antioxidants Article Implications of Oxidative Stress in Glioblastoma Multiforme Following Treatment with Purine Derivatives Marta Orlicka-Płocka 1,† , Agnieszka Fedoruk-Wyszomirska 1,† , Dorota Gurda-Wo´zna 1 , Paweł Pawelczak 1 , Patrycja Krawczyk 2, Małgorzata Giel-Pietraszuk 1, Grzegorz Framski 1 , Tomasz Ostrowski 1 and Eliza Wyszko 1,* 1 Institute of Bioorganic Chemistry, Polish Academy of Sciences, Noskowskiego 12/14, 61-704 Poznan, Poland; [email protected] (M.O.-P.); [email protected] (A.F.-W.); [email protected] (D.G.-W.); [email protected] (P.P.); [email protected] (M.G.-P.); [email protected] (G.F.); [email protected] (T.O.) 2 MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, UK; [email protected] * Correspondence: [email protected] † Equally contributed as the first author. Abstract: Recently, small compound-based therapies have provided new insights into the treatment of glioblastoma multiforme (GBM) by inducing oxidative impairment. Kinetin riboside (KR) and newly designed derivatives (8-azaKR, 7-deazaKR) selectively affect the molecular pathways crucial for cell growth by interfering with the redox status of cancer cells. Thus, these compounds might serve as potential alternatives in the oxidative therapy of GBM. The increased basal levels of reactive oxygen species (ROS) in GBM support the survival of cancer cells and cause drug resistance. The simplest Citation: Orlicka-Płocka, M.; approach to induce cell death is to achieve the redox threshold and circumvent the antioxidant Fedoruk-Wyszomirska, A.; defense mechanisms. Consequently, cells become more sensitive to oxidative stress (OS) caused by Gurda-Wo´zna,D.; Pawelczak, P.; exogenous agents.
    [Show full text]
  • Purine and Pyrimidine Metabolism in Human Epidermis* Jean De Bersaques, Md
    THE JOURNAL OP INVESTIGATIVE DERMATOLOGY Vol. 4s, No. Z Copyright 1957 by The Williams & Wilkins Co. Fri nte,1 in U.S.A. PURINE AND PYRIMIDINE METABOLISM IN HUMAN EPIDERMIS* JEAN DE BERSAQUES, MD. The continuous cellular renewal occurring inthine, which contained 5% impurity, and for uric the epidermis requires a very active synthesisacid, which consisted of 3 main components. The reaction was stopped after 1—2 hours in- and breakdown of nuclear and cytoplasmiecubation at 37° and the products were spotted on nucleic acids. Data on the enzyme systemsWhatman 1 filter paper sheets. According to the participating in these metabolic processes arereaction products expected, a choice was made of rather fragmentary (1—9) and some are, inat least 2 among the following solvents, all used terms of biochemical time, in need of up- in ascending direction: 1. isoamyl alcohol—5% Na2HPO4 (1:1), dating. In some other publications (10—18), 2. water-saturated n-butanol, the presence and concentration of various in- 3. distilled water, termediate products is given. 4. 80% formic acid—n-hutanol——n-propanol— In this paper, we tried to collect and supple- acetone—30% trichloro-aeetic acid (5:8:4: ment these data by investigating the presence 5:3), 5. n-butanol——4% boric acid (43:7), or absence in epidermis of enzyme systems 6. isobutyrie acid—water—ammonia 0.880—ver- that have been described in other tissues. sene 0.1M(500:279:21:8), This first investigation was a qualitative one, 7. upper phase of ethyl acetate—water—formic and some limitations were set by practical acid (12:7:1), 8.
    [Show full text]
  • 214 Thymidine Incorporation in Nucleoside Transport
    REGULATION OF ENZYMES BY LIGAND INDUCED CHANGE IN THYMIDINE INCORPORATION IN NUCLEOSIDE TRANSPORT 211 POLYMERIZATION. 214 DEFICIENT T LYMPHOMA CELLS. Buddy Ullman and Bruce Thomas W. Traut, Nancy Cheng, and Margaret M. Aronow. Univ. KY Medical Center, -- Matthews, University of North Carolina School of Medicine, Biochemistry, Lexington, KY, U.S.A. Nucleoside transport Department of Biochemistry, Chapel Hill, North Carolina , USA deficiency in mammalian cells is generally associated with an Many enzymes readily change their aggregation state, by inability to transport all nucleosides and an inability to bind dissociation or association of subunits. This constitutes a or be affected by p-nitrobenzylthioinosine (NBMPR), a potent mechanism for regulation, if the different molecular weight spe­ inhibitor of nucleoside transport. Among nucleoside cies vary in their specific activity, and if the equilibrium transport-deficient (NT-) 549 T lymphoma clones, however, the between these species is readily perturbed by physiological ability to take up and respond to the physiological effects of effectors. Our studies show that several enzymes involved in thymidine varied considerably. The NT- clone, AEJ, was the synthesis or degradation of pyrimidines exhibit such regula­ almost as capable of incorporating thymidine into TTP as the tion: The multifunctional protein UMP synthase (EC 2.4.2.10 + wildtype parent. This incorporation of thymidine into TTP by EC 4.1.1.23), and uridine kinase (EC 2.7 . 1.48) from Ehrlich AE 1 cells and a large percentage of thymidine incorporation ascites cells, and N-carbamoyl-P-alanine amidohydrolase into TTP by wildtype cells were unresponsive to NBMPR. Thus, (EC 3.5.1.6) from rat liver .
    [Show full text]
  • Defects in Metabolism of Purines and Pyrimidines
    Ned Tijdschr Klin Chem 1999; 24: 171-175 Defects in metabolism of purines and pyrimidines A.H. van GENNIP Defects in the metabolism of purines and pyrimidines To date 27 defects of purine and pyrimidine metabo- are not well-known in the general hospital. For this lism have been documented. They are listed in Tables reason relatively few patients suffering from these 1 and 2. diseases are being diagnosed. However, at present 27 different defects of purine- and pyrimidine metabo- Diagnosis lism have already been documented. Clinically, these In purine metabolism uric acid is the end product of defects are not easily recognised, at least for the larger biosynthesis 'de novo', salvage and degradation and part, because of non-specific symptoms. Therefore, therefore measurement of uric acid in plasma and the assistance of a clinical chemistry laboratory spe- urine will lead to an indication for several purine cialized in inborn errors is indispensable to discover defects but certainly not all defects (table 1). Pyrim- most of these defects. This review describes the various idine metabolism does not have such an end product. biochemical and clinical aspects of the defects of purine Moreover, as in many inborn errors of metabolism and pyrimidine metabolism and provides a guide for clinical symptomatology is aspecific and highly variable their detection, diagnosis and treatment. (Table 3). Therefore, screening methods covering a broad spectrum of purine and pyrimidine metabolites Definition and frequency will provide the best possibility of detecting most of Defects of purine and pyrimidine metabolism are the known defects or even new defects. Such methods characterized by abnormal concentrations of purines, are already operative in many centres around the pyrimidines and/or their metabolites in cells or body world for amino acids, organic acids, mucopolys- fluids due to a decreased or an increased activity of accharides and oligosaccharides.
    [Show full text]
  • Fabrication of a Novel Shaped Graphene/Poly (Evan's Blue
    Anal. Bioanal. Electrochem., Vol. 11, No. 8, 2019, 1100-1116 Archive of SID Analytical & Bioanalytical Electrochemistry 2019 by CEE www.abechem.com Full Paper Fabrication of a Novel Shaped Graphene/poly (Evan’s blue) Composite Chemical Sensor for the Electrocatalytic Boost up of Neurotransmitter (Dopamine): A Voltammetric Investigation G. Venkataprasad, T. Madhusudana Reddy,* T. Venu Gopal, P. Shaikshavali and P. Gopal Electrochemical Research Laboratory, Department of Chemistry, S.V.U. College of Sciences, Sri Venkateswara University, Tirupati-517502, Andhra Pradesh, India *Corresponding Author, Tel.: +91-877-2289303 E-Mail: [email protected] Received: 8 July 2019 / Received in revised form: 1 August 2019 / Accepted: 8 August 2019 / Published online: 31 August 2019 Abstract- A facile, sensitive and selective electrochemical sensor was fabricated based on electropolymerization of Evan’s blue (Eb) (Poly(Eb)) on the carbon paste electrode (CPE) followed by drop casting of graphene (GR) onto the Poly(Eb)/CPE. The electrochemical behaviour of dopamine (DA) at the surface of GR/Poly(Eb)/CPE was studied. Moreover, the surface morphology of various types of modified electrodes was characterised by electrochemical impedance spectroscopy (EIS) and scanning electron microscope (SEM). The proposed electrochemical sensor has successfully facilitated the simultaneous resolution of DA in presence of uric acid (UA) and folic acid (FA). A good linear relationship was observed for the detection of DA in the range between 5-110 µM, with the lower detection limit of 6.52 µM. The analytical application of GR/Poly(Eb)/CPE was also studied towards the detection of dopamine in real sample analysis with good recovery results.
    [Show full text]
  • “The Role of Xanthine Oxidase Inhibiting Foods in Therapeutic Management of Hyperuricemia and Gout”
    International Journal of Research in Social Sciences Vol. 8 Issue 11, November 2018, ISSN: 2249-2496 Impact Factor: 7.081 Journal Homepage: http://www.ijmra.us, Email: [email protected] Double-Blind Peer Reviewed Refereed Open Access International Journal - Included in the International Serial Directories Indexed & Listed at: Ulrich's Periodicals Directory ©, U.S.A., Open J-Gage as well as in Cabell’s Directories of Publishing Opportunities, U.S.A “The role of Xanthine Oxidase Inhibiting Foods in Therapeutic Management of HyperurIcemIa and Gout” 1Dr Luxita Sharma * 2 ** Zarrin Ashraf Abstract The state of equilibrium created between the amount of purine taken in diet, urate produced by the body itself along with the amount excreted out of the body through urine or GI tract gives out the total urate present in the body. Faulty production and excretion both can be the reason behind increased level of uric acid. Default in dietary habits has always been primary, secondary or associated cause of many ailments. Similarly in case of gout intake of purine- rich foods basically coming from animal and seafood sources can influence the development of gout. Allopurinol, is one of the potent anti-hyperuricemia drugs, being used for the treatment of gout for last many years. The mechanism of action of this drug involves the inhibition of enzyme xanthine oxidase. But long term use of allopurinol has already been associated with many side effects such nephropathy, hepatitis and many other allergic reactions. There is a need of natural anti-hyperuricemic agents.Herbs and plants that show the properties of inhibition of uric acid biosynthesis through the inhibition of xanthine oxidase can prevent hyperuricemia.In conclusion, natural antihyperuricemic agents need promotion.
    [Show full text]
  • Purine and Pyrimidine Metabolism by N. ZOLLNER, Department Of
    Proc. Nuti. Soc. (1982), 41,329 329 Purine and pyrimidine metabolism By N. ZOLLNER,Department of Medicine, University of Munchen, West Germany Purines and pyrimidines are essential constituents of animal and plant cells and are contained in various compounds. It is interesting to consider that some of these compounds are very stable, e.g. DNA, while others are rapidly turned over, e.g. ATP. In birds and reptiles uric acid also serves to excrete nitrogen. The aim of this paper is to give a short review of purine and pyrimidine metabolism and to describe in some detail aspects important to the field of nutrition, with emphasis placed on work done in vitro and in man. Purines The most important structure in purine biochemistry is the nucleotide consisting of a purine base, ribose or deoxyribose, and phosphoric acid. The most important purine bases are adenine, guanine, hypoxanthine and xanthine. The ribosides of all of them are known to occur in metabolism. Adenine and guanine themselves are usually not found in the tissues of mammals, but free hypoxanthine and xanthine are intermediates in the degradation of purines. Uric acid is a divalent acid, but the second dissociation constant is so small that at around pH 7 only the monobasic salts are formed. These are sparingly soluble in the body fluids. Peters & van Slyke (1946) have calculated a maximum solubility of 6.5 mg/Ioo ml (as uric acid) in plasma. Gout and uric acid nephropathies are due to this low solubility. Nucleosides are pentose-glycosides containing ribose or deoxyribose. Normally the linkage is with atom 9, but nucleosides with atom 3 do occur.
    [Show full text]